Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT05859126
Other study ID # IRB0147236
Secondary ID
Status Enrolling by invitation
Phase N/A
First received
Last updated
Start date June 23, 2023
Est. completion date December 2024

Study information

Verified date February 2024
Source Cornell University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this 13-year follow up of a randomized control trial is to study the effect of maternal choline supplementation on offspring cognition in adolescence. The main question[s] it aims to answer are: Does a higher dose of maternal choline choline (930 mg/d day supplementation) lead to improved cognition in adolescence including hippocampal-dependent episodic memory and executive functioning when compared to lower dose supplementation (480 mg/d). In this follow-up of a clinical trial participants will complete online cognition testing and emotion testing.


Description:

Eggs are one of the richest dietary sources of choline, an essential nutrient that plays critical roles in fetal development, including shaping the structure and function of the offspring brain. Furthermore, evidence shows that pregnancy dramatically increases the demand for choline. In rodents consuming standard chow, pregnancy results in a pronounced depletion of maternal choline pools, indicating that choline requirements during pregnancy are increased and that maternal and fetal requirements likely exceed the amount typically consumed by mothers. Additionally, human research from the investigators' laboratory has found that the "Adequate Intake" (AI) levels for choline during pregnancy, set in 1998 and based on the amount needed to prevent liver damage in adult men, may not be sufficient to meet the demands of pregnancy. Specifically, pregnant women consuming choline at the AI level have significantly lower circulating concentrations of several choline metabolites compared to non-pregnant women, and even doubling maternal choline intake (to twice the AI) fails to produce the metabolite levels observed in non-pregnant women. Perhaps most importantly, a substantial body of experimental research in animal models demonstrates that supplementation with additional choline during pregnancy significantly improves lifelong memory, attention, and emotional regulation in offspring, re-duces or eliminates normal ageing-related decline in cognitive function, and reduces the im-pact of a range of prenatal neural insults (e.g., alcohol exposure, maternal stress). Despite extensive experimental data in animal models demonstrating lasting beneficial effects of maternal choline supplementation on offspring memory, attention, and affect, few studies have evaluated the effects of increasing maternal choline intake in humans. Moreover, results from existing human studies are not sufficiently conclusive to alter dietary intake recommendations for pregnancy. However, a randomized choline feeding trial from the investigators' laboratory demonstrated beneficial effects of increased maternal choline intake (930 mg/d vs. 480 mg/d) on offspring cognitive functioning during infancy and at 7 years of age (work supported in part by previous ENC funding). Based on these findings, the investigators propose to follow up children born to mothers participating in this trial, to examine longer-term effects of maternal choline supple-mentation on child cognition and emotional well-being at thirteen years of age. This will be the first randomized controlled trial (RCT) following children into adolescence, a time when tests are highly predictive of adult functioning. Choline is an essential nutrient that plays critical roles in fetal neurodevelopment. The demand for choline increases markedly during pregnancy, indicated by a pronounced depletion of maternal choline pools even when women consume the Adequate Intake (AI) level. It is a concern that fewer than 10% of reproductive age women achieve the recommended AI level, and that choline is not included in standard prenatal vitamin regimens. Decades of rodent studies show that maternal choline intake affects offspring brain structure, neural function and cognitive performance throughout life the lifespan. Maternal choline deficiency produces lasting offspring cognitive impairment, whereas increasing maternal choline intake markedly improves offspring cognition and provides widespread neuroprotection in various diseases and early insults. Only 3 Randomized Controlled Trials (RCTs) have evaluated offspring cognition following maternal choline supplementation (MCS) in healthy human pregnancies. One trial conducted in the investigators' lab demonstrated that MCS improves offspring cognition during infancy and early childhood, but no studies have yet determined whether the beneficial effects observed in the immature human brain are maintained in adulthood. This question can be addressed by assessing the cognitive performance of MCS offspring in adolescence, a time when many neurocognitive tests are strong predictors of ultimate adult functioning. The planned study will take advantage of the unique opportunity to follow up the offspring of women who participated in a controlled feeding study comparing two levels of choline intake during pregnancy: 480 vs 930 mg/d. The offspring will be tested at 13 years old, an age when cognitive functioning predicts adult functioning. The investigators predict that the cognitive performance of the children born to women consuming 480 mg/d (approximately the AI) during the last trimester of pregnancy will be poorer than children born to women consuming 930 mg/d. The predicted results would strongly indicate that the low choline intake of most pregnant women impedes the lifelong cognitive functioning of their children. Demonstrating this effect would spur the addition of choline to standard prenatal vitamin regimens-the predicted result being population-wide improvements in cognitive functioning, in part due to widespread neuroprotection. These effects would be particularly beneficial for at-risk pregnancies and underserved populations.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 26
Est. completion date December 2024
Est. primary completion date July 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 13 Years to 13 Years
Eligibility Inclusion Criteria: - Offspring of mothers from the original choline feeding trial - Testing will commence when the child reaches 13 years of age (determined by date of birth of participant) Exclusion Criteria: - Failure to follow the study protocol regarding test procedures and questionnaires - Lack of internet access with the requisite speed and stability needed to support the online testing tools

Study Design


Intervention

Dietary Supplement:
Maternal Choline Supplementation 930 mg/d
Mothers were supplemented with choline (930mg/d) from second trimester through birth. This is a 13 year follow up of their offspring.
Maternal Choline Supplementation 480 mg/d
Mothers were supplemented with choline (480 mg/d) from second trimester through birth. This is a 13 year follow up of their offspring.

Locations

Country Name City State
United States Cornell University, Division of Nutritional Sciences Ithaca New York

Sponsors (1)

Lead Sponsor Collaborator
Cornell University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary CANTAB Signal Detection test To measure selective and sustained attention where sensitivity to stimulus ranges from 0 (bad) to 1 (good) at 13 years of age
Primary CANTAB Delayed Matching to Sample To measure memory where scoring is based on percent correct where 0% is bad and 100% is excellent), Paired Associates Learning (where scoring is based on total errors, where 0 is best), and Pattern Recognition Memory (where outcome is measured as percentage of correct trials and latency (speed of participant's response).) at 13 years of age
Primary CANTAB Spatial Working Memory To measure executive function (where outcome measure is number of errors and lower is better), at 13 years of age
Primary CANTAB Cambridge Gambling To measure executive function (where outcome measure is number of errors and lower is better), at 13 years of age
Secondary Child Behavior Checklist (CBCL) To measure emotion regulation where scoring is from 0-226 and lower is better. at 13 years of age
Secondary Youth Self Report (CBCL To measure emotion regulation where scoring is from 0-226 and lower is better. at 13 years of age
See also
  Status Clinical Trial Phase
Recruiting NCT04111549 - GOALS Cognitive Training Delivered to Aging Veterans in Person or Via Telehealth N/A
Completed NCT02122198 - Vascular Mechanisms for the Effects of Loss of Ovarian Hormone Function on Cognition in Women N/A
Enrolling by invitation NCT05017779 - A Hybrid Effectiveness-implementation Trial of a High School-based Executive Function Treatment for Autistic Youth N/A
Terminated NCT02416193 - Can Vitamin D3 Improve Cognitive Function in Individuals With Type 2 Diabetes? (THINK-D) Phase 2
Recruiting NCT06073717 - Motor-cognitive Training Effects on Cognition in Breast Cancer Survivors: the BRAINonFIT Study (BRAINonFIT). N/A
Completed NCT02613936 - Transcranial Direct Current Stimulation for the Treatment of Deficits After Traumatic Brain Injury N/A
Recruiting NCT05874791 - Executive Control Training for Adolescents With ADHD: A Randomized Controlled Effectiveness Trial N/A
Recruiting NCT04465708 - HOPS Study: A Conceptual Replication N/A
Active, not recruiting NCT05131659 - Intervention-Induced Plasticity of Flexibility and Learning Mechanisms in ASD N/A
Active, not recruiting NCT04121650 - Executive Function and Symptom Reduction in Youth Receiving Home-based Treatment With Collaborative Problem Solving
Completed NCT04221841 - Executive Functions and Reinforcement Sensitivity in Women With Obsessive Compulsive Symptoms
Completed NCT03490110 - Brain Markers of Improvements in Cognitive Functioning N/A
Completed NCT03285347 - Effect of Computer-based Cognitive Training on Attention and Executive Functions in Patients With Parkinson's Disease N/A
Completed NCT03073122 - The Boston Circulatory Arrest Study: Antecedents and Correlates of Well-Being in Adults With Congenital Heart Disease
Completed NCT03958487 - An Executive/Monitoring Treatment Protocol on Everyday Life Activities N/A
Completed NCT02091167 - Bilateral Prefrontal Modulation in Crack-cocaine Addiction Phase 2
Completed NCT02091284 - Bilateral Prefrontal Modulation in Alcoholism N/A
Completed NCT01730261 - Online Emotional Regulation Group Treatment Phase 1
Completed NCT00271596 - Citalopram to Enhance Cognition in HD Phase 2
Active, not recruiting NCT04108728 - Neuropsychological Development and Executive Functioning of Children Born to HIV- Infected Mothers ( NEUROPSY-HEU ) N/A